产品
编 号：F762955
分子式：C27H21F3N4O5
分子量：538.47
分子式：C27H21F3N4O5
分子量：538.47
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 3026111-74-7
产品详情
生物活性：
TrkA-IN-4, a potent, orally active and allosteric TrkA inhibitor, is a proagent of TrkA-IN-3 (IC50=22.4 nM, HY-151948). TrkA-IN-4 exhibits potent antinociceptive effects.
体内研究：
TrkA-IN-4 (compound 39) (0.9375-120 mg/kg; i.g.) exhibits stronger maximum antinociceptive effects 3 h after administration, with an ED50 of 7.836 mg/kg in hot plate testing on male mice.Animal Model:KM male mice (20-24 g) were received hot plate test
Dosage:0.9375, 1.875, 3.75, 7.5, 15, 30, 60, 120 mg/kg
Administration:A single i.g.
Result:3 h after administration, exhibited potent antinociceptive effects, with an ED50 of 7.836 mg/kg.
体外研究：
TrkA-IN-4 (compound 39) demonstrates 65.1% and 46.3% of kinase inhibition towards TrkA at concentrations of 1 μM and 0.1 μM, respectively.
TrkA-IN-4, a potent, orally active and allosteric TrkA inhibitor, is a proagent of TrkA-IN-3 (IC50=22.4 nM, HY-151948). TrkA-IN-4 exhibits potent antinociceptive effects.
体内研究：
TrkA-IN-4 (compound 39) (0.9375-120 mg/kg; i.g.) exhibits stronger maximum antinociceptive effects 3 h after administration, with an ED50 of 7.836 mg/kg in hot plate testing on male mice.Animal Model:KM male mice (20-24 g) were received hot plate test
Dosage:0.9375, 1.875, 3.75, 7.5, 15, 30, 60, 120 mg/kg
Administration:A single i.g.
Result:3 h after administration, exhibited potent antinociceptive effects, with an ED50 of 7.836 mg/kg.
体外研究：
TrkA-IN-4 (compound 39) demonstrates 65.1% and 46.3% of kinase inhibition towards TrkA at concentrations of 1 μM and 0.1 μM, respectively.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备